Caribou Cut a Third of Its Team to Bet the Company on Two Cancer Drugs - Here’s What Focus Costs in Biotech

The CRISPR pioneer traded a sprawling platform story for two off-the-shelf cancer therapies, a smaller herd, and a very specific test: can ready-made CAR-T match custom-built medicine before the cash clock runs out?